Trinity Life Sciences (Trinity) recently announced the acquisition of Illinois-headquartered and India-based D Cube Analytics. The acquisition adds extensive data science and digital transformation capabilities to Trinity’s growing commercialization portfolio.
D Cube’s bespoke analytics platforms, purpose built for life sciences companies, help extract maximum value out of data investments and facilitate decision-making to achieve commercial outcomes more effectively and efficiently.
Originally founded in 1996 as Trinity Partners, Trinity has since grown to comprise a global team of advisors, technical experts, data integrators, and technology innovators.
Trinity’s approach is focused on its foundation of three: advisory services, insights & analytics, and technology. By seamlessly integrating each of these solutions, the company can meet the distinct needs of both emerging biotech firms and established pharmaceutical companies.
In October 2021, Trinity acquired CBPartners to bolster the company’s Value, Access and Pricing business. The combination of Trinity’s commercial strategy and solutions, augmented by CBPartners’ expertise in the value, access and pricing space, will better empower life sciences companies to commercialize their innovations and ensure access for patients.
Since then, the company announced the significant expansion of its pricing and market access offerings. The expanded team is made up of both functional experts as well as a talented pool of centralized staff who work across project types. The two segments include:
- Evidence Strategy – provides end-to-end evidence strategy and planning, execution of publication-grade studies and pull-through to scientific dissemination.
- Value, Access and Pricing – delivers innovative and locally-nuanced global solutions for value, market access and pricing development and execution support.
Trinity also recently launched Government Pricing (GP) services within TGaS Advisors. The new services help pre-commercial and emerging life sciences companies develop their GP policies and methodologies and provide support for ongoing GP calculations.
Takeaway: The leading commercialization companies are rapidly adding product and service capabilities to offer a robust commercialization portfolio to life science companies